Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

VIEWPOINTS_Kurt Harrington_2024
Alternative Treatment: Kurt Harrington from Ventoux Biosciences in a Gripping Conversation with PharmaShots
Shots:  Dupuytren’s disease is a chronic progressive & debilitating fibrosis that impacts hands. There’s an unmet need to treat Dupuytren’s disease, especially when looking for a pharmacological substitute for surgical interventions  Today, at PharmaShots, we had the pleasure to speak with Kurt Harrington, CEO and Founder of Ventoux Biosciences  Kurt shares insights from the preclinical…
May 29, 2024
VIEWPOINTS_Jason Hannon_2024
Funds Raised: Jason Hannon from Mainstay Medical in a Stimulating Conversation with PharmaShots
Shots:  Mainstay Medical recently raised $125M in the company’s largest funding round. The financing is intended to accelerate the commercial growth of the company’s ReActiv8, a restorative Neurostimulation therapy in the US, Europe, and Australia  Today, at PharmaShots, we had Jason Hannon, CEO of Mainstay Medical, who talked in great length about the ReActiv8 Restorative Neuromodulation System developed for…
May 27, 2024
VIEWPOINTS_Jeffrey Lengyel_2024
Increasing Accessibility: Jeffrey Lengyel from Thermo Fisher Scientific, in an Enlightening Conversation with PharmaShots
Shots:   Advances in Cryo-EM help better understand biological molecules and complexes at atomic resolution. Thermo Fisher Scientific’s recently launched Glacios 2 Cryo-TEM with E-CFEG offers promising potential in reducing the workflow complexities with automation  Today, we have Jeffrey Lengyel Director of Life Sciences, Cryo-EM, at Thermo Fisher Scientific shedding light on Glacios 2 Cryo-TEM with E-CFEG  Jeffrey highlights the significance of the…
May 22, 2024
VIEWPOINTS_Dror Zur_2024
AI-Aided Colonoscopy Technology: Dror Zur from Magentiq Eye in a Dialogue Exchange with PharmaShots
Shots:  Dror Zur, CEO and Founder of Magentiq Eye in a stimulating conversation with PharmaShots talks about the Lancet Digital Health Study journal that featured MAGENTIQ-COLO™, an AI-aided colonoscopy technology study  MAGENTIQ-COLO™ has already got FDA clearance and a CE mark for polyp detection during colonoscopy. The renewed version includes features like polyp size estimation, polyp characterization, and additional…
May 13, 2024
VIEWPOINTS_Meri Beckwith _2024
Infusing AI in Clinical Trials: Meri Beckwith from Lindus Health in Conversation with PharmaShots
Shots:  Meri Beckwith, Co-Founder of Lindus Health engages in a striking conversation with PharmaShots  Meri talks about bridging the gaps of clinical trials in CNS/Neurology by leveraging LLMs that are trained on nearly a million clinical trial protocols and simple machine learning models to monitor real-time clinical trial data  Meri highlights the importance of multidisciplinary…
May 8, 2024
VIEWPOINTS_Salomé Juethner_2024
Takeda at AAAAI 2024: Salomé Juethner highlights P-IV Results from ENABLE and EMPOWER Studies
Shots:  At the American Academy of Allergy, Asthma, & Immunology (AAAAI), Takeda presented 9 abstracts focusing on health equity and real-world data from P-IV (ENABLE) & (EMPOWER) studies evaluating HAE patients  Salomé Juethner, Senior Medical Director-Head of Rare Genetics at Takeda, in a stimulating conversation with PharmaShots, talks about shares insights from the real-world P-IV…
May 6, 2024
VIEWPOINTS_Angela Cacace_2024
Transformative Neurodegenerative Disorder Care: Angela Cacace in Conversation with PharmaShots
Shots: Angela Cacace Sr. VP, of Neuroscience and Platform Biology at Arvinas, shares insights from the preclinical trials evaluating ARV-102 for treatment of neurodegenerative diseases and dosing people with the first oral formulation (ARV-102) to treat neurodegenerative diseases ARV-102, a novel oral PROTAC® protein degrader, is designed to cross the blood-brain barrier and target leucine-rich repeat kinase…
April 29, 2024
VIEWPOINTS_Raviv Pryluk_2024
Technology Infusion: Raviv Pryluk Sheds Light on PhaseV’s Recent Collaboration with 9xchange Biopharma Marketplace
Shots:   Raviv Pryluk, CEO and Co-Founder of PhaseV, in a stimulating conversation with PharmaShots, sheds light on the company’s recent partnership with 9xchange Biopharma    The partnership aims to bring Phase V’s proprietary machine learning (ML) technology to ecosystem members, enabling them, to retrospectively analyze and optimally design and execute advanced clinical studies   Raviv highlights the…
April 23, 2024
Load more